Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilpivirine plus darunavir/cobicistat switch study in virologically suppressed HIV-1 patients
2016-003948-36Phase 3Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rilpivirine, darunavir and cobicistat in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Primary efficacy endpoint. Started Sep 2021; status: completed.
02
Drugs
rilpivirinedarunavircobicistat
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2016-003948-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003948-36.